Intermittent fasting

Based on the provided literature, the consensus surrounding intermittent fasting and time-restricted eating (TRE) is that while these dietary regimens impact health and disease processes [6], their metabolic benefits in humans can be statistically significant yet clinically modest [9]. In the broader context of metabolic health, conditions like obesity and metabolic syndrome induce chronic oxidative stress, inflammation, and insulin resistance [3, 5], which are foundational precursors to type 2 diabetes and cardiovascular complications [2, 5]. Intermittent fasting is frequently investigated as a lifestyle intervention to ameliorate these metabolic dysregulations.

Open questions remain regarding the specific physiological and downstream clinical efficacy of intermittent fasting regimens, particularly concerning variables such as optimal fasting windows, long-term adherence, and secondary outcomes like alterations in the gut microbiota [9]. Furthermore, while metabolic syndrome and obesity involve distinct cellular perturbations—such as skeletal muscle mitochondrial dysfunction(definition) [1] and adipose-driven inflammatory mediator release [3]—the precise molecular mechanisms by which intermittent fasting reverses or mitigates these specific tissue-level dysfunctions require further clarification.

The strength of evidence for the broader metabolic consequences of energy imbalance (such as oxidative stress, inflammation, and insulin resistance) is robust and supported by numerous clinical and mechanistic studies [1, 2, 3, 5, 8]. However, the direct evidence specifically evaluating intermittent fasting and time-restricted eating in real-life human settings remains limited, characterized by small cohort sizes and modest clinical impact [9].